SCHEMBL4342198

SCHEMBL4342198

Cc1ccc(Sc2ccccc2CNc2ccc(O)cc2O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
GFER P55789 2/20 0.44
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 1/20 0.42
G6PD P11413 1/20 0.42
PKM P14618 1/20 0.42
RECQL P46063 1/20 0.42
CCR6 P51684 1/20 0.42
MCL1 Q07820 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353649 0.90 SMN1; SMN2 (0.48) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4348367 0.88 SLC6A4 (0.46) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4342287 0.87 KMT2A (0.58) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL12846793 0.85 MAPT (0.50) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4346228 0.84 MAPT (0.43) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4346759 0.83 SMN1; SMN2 (0.41) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4356009 0.82 MAPT (0.46) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL4357675 0.81 MAPT (0.44) MAPTSMN1; SMN2GFERALDH1A1HPGD
SCHEMBL4343713 0.81 SLC6A4 (0.44) MAPTSMN1; SMN2ALDH1A1MAPK1KDM4E
SCHEMBL4358394 0.81 SLC6A4 (0.50) MAPTSMN1; SMN2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885SMN1; SMN2 1791/4885CYP2D6 191/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPT 4184/4885SMN1; SMN2 3250/4885CYP2D6 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.